雷诺嗪用于慢性全闭塞经皮冠状动脉介入治疗。

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Invasive Cardiology Pub Date : 2024-10-01 DOI:10.25270/jic/24.00059

Michaella Alexandrou, Deniz Mutlu, Athanasios Rempakos, Ahmed Al Ogaili, James W Choi, Paul Poommipanit, Khaldoon Alaswad, Mir Babar Basir, Rhian Davies, Farouc A Jaffer, Phil Dattilo, Lorenzo Azzalini, Nazif Aygul, Niranjan Reddy, Brian K Jefferson, Sevket Gorgulu, Jaikirshan J Khatri, Laura D Young, Oleg Krestyaninov, Dmitrii Khelimskii, Jarrod Frizzell, Basem Elbarouni, Bavana V Rangan, Olga C Mastrodemos, M Nicholas Burke, Yader Sandoval, Emmanouil S Brilakis

{"title":"雷诺嗪用于慢性全闭塞经皮冠状动脉介入治疗。","authors":"Michaella Alexandrou, Deniz Mutlu, Athanasios Rempakos, Ahmed Al Ogaili, James W Choi, Paul Poommipanit, Khaldoon Alaswad, Mir Babar Basir, Rhian Davies, Farouc A Jaffer, Phil Dattilo, Lorenzo Azzalini, Nazif Aygul, Niranjan Reddy, Brian K Jefferson, Sevket Gorgulu, Jaikirshan J Khatri, Laura D Young, Oleg Krestyaninov, Dmitrii Khelimskii, Jarrod Frizzell, Basem Elbarouni, Bavana V Rangan, Olga C Mastrodemos, M Nicholas Burke, Yader Sandoval, Emmanouil S Brilakis","doi":"10.25270/jic/24.00059","DOIUrl":null,"url":null,"abstract":"Ranolazine is an anti-anginal medication given to patients with chronic angina and persistent symptoms despite medical therapy. We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).","PeriodicalId":49261,"journal":{"name":"Journal of Invasive Cardiology","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ranolazine in chronic total occlusion percutaneous coronary intervention.\",\"authors\":\"Michaella Alexandrou, Deniz Mutlu, Athanasios Rempakos, Ahmed Al Ogaili, James W Choi, Paul Poommipanit, Khaldoon Alaswad, Mir Babar Basir, Rhian Davies, Farouc A Jaffer, Phil Dattilo, Lorenzo Azzalini, Nazif Aygul, Niranjan Reddy, Brian K Jefferson, Sevket Gorgulu, Jaikirshan J Khatri, Laura D Young, Oleg Krestyaninov, Dmitrii Khelimskii, Jarrod Frizzell, Basem Elbarouni, Bavana V Rangan, Olga C Mastrodemos, M Nicholas Burke, Yader Sandoval, Emmanouil S Brilakis\",\"doi\":\"10.25270/jic/24.00059\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ranolazine is an anti-anginal medication given to patients with chronic angina and persistent symptoms despite medical therapy. We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).\",\"PeriodicalId\":49261,\"journal\":{\"name\":\"Journal of Invasive Cardiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Invasive Cardiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.25270/jic/24.00059\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Invasive Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.25270/jic/24.00059","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

雷诺拉嗪是一种抗心绞痛药物，适用于接受药物治疗后仍有持续症状的慢性心绞痛患者。我们研究了 PROGRESS-CTO 注册中心在 2012 年至 2023 年间在 41 个美国和非美国中心实施的 11 491 例慢性全闭塞（CTO）经皮冠状动脉介入治疗（PCI）。基线时服用雷诺拉嗪的患者有更多的合并症、更复杂的病变、更低的手术成功率和技术成功率（基于单变量分析，而非多变量分析），以及更高的主要心脏不良事件（MACE）发生率（基于单变量分析和多变量分析）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Ranolazine in chronic total occlusion percutaneous coronary intervention.

Ranolazine is an anti-anginal medication given to patients with chronic angina and persistent symptoms despite medical therapy. We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Invasive Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.90

自引率

6.70%

发文量

214

审稿时长

3-8 weeks

期刊介绍： The Journal of Invasive Cardiology will consider for publication suitable articles on topics pertaining to the invasive treatment of patients with cardiovascular disease.